search
Back to results

Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation (ACCO)

Primary Purpose

Adenoid Cystic Carcinoma

Status
Recruiting
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
Carbon ion irradiation
Bimodal irradiation
Sponsored by
Heidelberg University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Adenoid Cystic Carcinoma focused on measuring carbon ion, heavy ion, salivary gland tumor, ACC, Radiation therapy

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histologically confirmed adenoid cystic carcinoma in the head and neck area
  • Indication for irradiation:
  • non-operable or
  • R1/R2 resected or
  • perineural sheat invasion (Pn+) or
  • pT3/pT4
  • Informed consent
  • KI > 60% or ECOG 0/1 (minimum: self-sufficiency, normal activity or work not possible)
  • Age 18-80 years

Exclusion Criteria:

  • rejection of the study by the patient
  • Patient is not able to consent
  • Stage IV (distant metastases), except lung metastases < 1cm
  • lymph node involvement (clinical or pathological)
  • Previous radiotherapy in the head and neck area
  • Active medical implants for which there is no ion radiation authorization at the time of treatment (e.g., cardiac pacemaker, defibrillator, ...)
  • Contraindication to MR imaging
  • Simultaneous participation in another clinical study that could influence the outcome of this study or the other study
  • Pregnancy

Sites / Locations

  • University of Heidelberg, Radiooncology, HITRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Carbon Ion irradiation

Bimodal Arm

Arm Description

22 x 3 Gy(RBE) Carbon Ions

25 x 2 Gy photon IMRT and 8 x 3 Gy(RBE) Carbon ion boost

Outcomes

Primary Outcome Measures

Freedom from loco-regional progression
Freedom from loco-regional tumor progression according to MR imaging

Secondary Outcome Measures

Progression-free survival
Progression-free survival
Overall survival
Overall survival
Acute toxicities
Acute toxicities according to NCI CTC AE (Version 5.0) (rate of toxicity > 2 grade)
Late toxicities
Late toxicities according to NCI CTC AE (Version 5.0) (rate of toxicity > 2 grade)

Full Information

First Posted
September 24, 2019
Last Updated
October 31, 2022
Sponsor
Heidelberg University
search

1. Study Identification

Unique Protocol Identification Number
NCT04214366
Brief Title
Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation
Acronym
ACCO
Official Title
Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2019 (Actual)
Primary Completion Date
December 1, 2027 (Anticipated)
Study Completion Date
December 1, 2032 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Heidelberg University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Adenoid cystic tumors are rare tumors of the head and neck region. Despite their slow growth, re-irradiation is often necessary due to the high metastatic risk. Patients are usually irradiated with photons or, as here at the Heidelberg University Hospital, with a combination of carbon ions and photons. So far, there is no data from Europe available for the sole irradiation with carbon ions. The present ACCO (Adenoid Cystic Carcinoma and Carbon ion Only irradiation) study, a prospective, open-label, phase II, single-arm, investigator-initiated study, will therefore investigate the sole radiotherapy of carbon ions in this tumor entity. Irradiation is applied - significantly shorter than the combination therapy - in about 4 weeks (22 fractions); patients are followed up for further 5 years after the start of therapy. Carbon ions alone are expected to increase local tumor control rates from 60% to 70% after 5 years (primary objective criterion of this study). In order to reject the null hypothesis with a power of 80% and a significance level of 5%, 175 patients are included (including a drop-out rate of 15%). Secondary objective criteria are progression-free survival, overall survival, acute and late toxicity, and quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adenoid Cystic Carcinoma
Keywords
carbon ion, heavy ion, salivary gland tumor, ACC, Radiation therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
314 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Carbon Ion irradiation
Arm Type
Experimental
Arm Description
22 x 3 Gy(RBE) Carbon Ions
Arm Title
Bimodal Arm
Arm Type
Active Comparator
Arm Description
25 x 2 Gy photon IMRT and 8 x 3 Gy(RBE) Carbon ion boost
Intervention Type
Radiation
Intervention Name(s)
Carbon ion irradiation
Intervention Description
22 x 3 Gy(RBE) Carbon Ions
Intervention Type
Radiation
Intervention Name(s)
Bimodal irradiation
Intervention Description
25 x 2 Gy photon IMRT + 8 x 3 Gy(RBE) Carbon ion boost
Primary Outcome Measure Information:
Title
Freedom from loco-regional progression
Description
Freedom from loco-regional tumor progression according to MR imaging
Time Frame
at 5 years
Secondary Outcome Measure Information:
Title
Progression-free survival
Description
Progression-free survival
Time Frame
at 3 and 5 years
Title
Overall survival
Description
Overall survival
Time Frame
at 3 and 5 years
Title
Acute toxicities
Description
Acute toxicities according to NCI CTC AE (Version 5.0) (rate of toxicity > 2 grade)
Time Frame
during and up to 6 weeks after radiotherapy
Title
Late toxicities
Description
Late toxicities according to NCI CTC AE (Version 5.0) (rate of toxicity > 2 grade)
Time Frame
up to 5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically confirmed adenoid cystic carcinoma in the head and neck area Indication for irradiation: non-operable or R1/R2 resected or perineural sheat invasion (Pn+) or pT3/pT4 Informed consent KI > 60% or ECOG 0/1 (minimum: self-sufficiency, normal activity or work not possible) Age 18-80 years Exclusion Criteria: rejection of the study by the patient Patient is not able to consent Stage IV (distant metastases), except lung metastases < 1cm lymph node involvement (clinical or pathological) Previous radiotherapy in the head and neck area Active medical implants for which there is no ion radiation authorization at the time of treatment (e.g., cardiac pacemaker, defibrillator, ...) Contraindication to MR imaging Simultaneous participation in another clinical study that could influence the outcome of this study or the other study Pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Klaus Herfarth, Prof. Dr.
Phone
+49 6221 56 8201
Email
klaus.herfarth@med.uni-heidelberg.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Klaus Herfarth, Prof. Dr.
Organizational Affiliation
University Hospital Heidelberg
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Heidelberg, Radiooncology, HIT
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Klaus Herfarth, Prof. Dr.
Phone
+49 6221 568201
Email
klausherfarth@med.uni-heidelberg.de
First Name & Middle Initial & Last Name & Degree
Klaus Herfarth, Prof. Dr.

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
34266402
Citation
Lang K, Adeberg S, Harrabi S, Held T, Kieser M, Debus J, Herfarth K. Adenoid cystic Carcinoma and Carbon ion Only irradiation (ACCO): Study protocol for a prospective, open, randomized, two-armed, phase II study. BMC Cancer. 2021 Jul 15;21(1):812. doi: 10.1186/s12885-021-08473-5.
Results Reference
derived

Learn more about this trial

Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation

We'll reach out to this number within 24 hrs